Aphria Germany Represents the Only Licensed
Producer Permitted to Cultivate All Three Approved Strains of
Medical Cannabis in Germany
LEAMINGTON, ON, May 21, 2019 /CNW/ - Aphria Inc. ("Aphria"
or the "Company") (TSX: APHA and NYSE: APHA) today
announced that its German subsidiary Aphria Deutschland GmbH
("Aphria Germany") had been awarded a fifth lot for the
cultivation of medical cannabis in Germany as part of the Company's previously
awarded license from the German Federal Institute for Drugs
and Medical Devices ("BfArM"). The additional lot was
provisionally awarded to Aphria Germany in April and was secured
following a review by a German court, which affirmed the original
decision by the BfArM.
With this decision, Aphria Germany won the maximum output from
the German tender process – a total of five lots - and stands as
the only licensed producer in Germany with the permission to grow all three
strains of medical cannabis approved by the BfArM.
"We are thrilled about our successful conclusion to the German
tender process, which has awarded Aphria with the most
comprehensive license in the country," said Hendrik Knopp, Managing Director of Aphria
Germany. "This award affirms Aphria's leading position in the
German medical cannabis market. Construction on our indoor
cultivation facility continues to progress rapidly and we look
forward to supplying Germany's
first domestically-grown medical cannabis in early calendar
2020."
Aphria Germany is building its over 8,000 square meter indoor
growing facility in Neumünster and is completing work on a
state-of-the-art GMP-certified cannabis vault in Bad
Bramstedt for the import of cannabis flowers and oil from
Canada, Australia and Denmark. Aphria Germany also holds a 25.1%
interest in Berlin-based
Schöneberg Hospital, which provides access to both doctors and
patients for education on the benefits of medical cannabinoids. The
company also recently introduced CannRelief, a CBD-based
nutraceutical and cosmetics product line for the German market,
produced in the EU and distributed by CC Pharma, a subsidiary of
Aphria with access to more than 13,000 pharmacies throughout
Germany.
We Have A Good Thing Growing
About Aphria Inc.
Aphria Inc. is a leading global
cannabis company driven by an unrelenting commitment to our people,
the planet, product quality and innovation. Headquartered in
Leamington, Ontario – the
greenhouse capital of Canada –
Aphria Inc. has been setting the standard for the low-cost
production of high-quality cannabis at scale, grown in the most
natural conditions possible. Focusing on untapped opportunities and
backed by the latest technologies, Aphria Inc. is committed to
bringing breakthrough innovation to the global cannabis market. The
Company's portfolio of brands is grounded in expertly-researched
consumer insights designed to meet the needs of every consumer
segment. Rooted in our founders' multi-generational expertise in
commercial agriculture, Aphria Inc. drives sustainable long-term
shareholder value through a diversified approach to innovation,
strategic partnerships and global expansion, with a presence in
more than 10 countries across 5 continents.
For more information, visit: aphriainc.com
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: Certain
information in this news release constitutes forward-looking
statements under applicable securities laws. Any statements that
are contained in this news release that are not statements of
historical fact may be deemed to be forward-looking statements.
Forward looking statements are often identified by terms such as
"may", "should", "anticipate", "expect", "potential", "believe",
"intend" or the negative of these terms and similar expressions.
Forward-looking statements in this news release include, but are
not limited to, statements with respect to internal expectations,
estimated margins, expectations with respect to actual production
volumes, expectations for future growing capacity and costs, the
completion of any capital project or expansions, and expectations
with respect to future production costs. Forward-looking statements
necessarily involve known and unknown risks, including, without
limitation, risks associated with general economic conditions;
adverse industry events; marketing costs; loss of markets; future
legislative and regulatory developments involving cannabis;
inability to access sufficient capital from internal and external
sources, and/or inability to access sufficient capital on
favourable terms; the cannabis industry in Canada generally, income tax and regulatory
matters; the ability of Aphria Inc. to implement its business
strategies; competition; crop failure; currency and interest rate
fluctuations and other risks.
Readers are cautioned that the foregoing list is not exhaustive.
Readers are further cautioned not to place undue reliance on
forward-looking statements as there can be no assurance that the
plans, intentions or expectations upon which they are placed will
occur. Such information, although considered reasonable by
management at the time of preparation, may prove to be incorrect
and actual results may differ materially from those
anticipated.
The forward-looking statements included in this news release are
made as of the date of this news release and the Company does not
undertake an obligation to publicly update such forward-looking
statements to reflect new information, subsequent events or
otherwise unless required by applicable securities laws.
Forward-looking statements contained in this news release are
expressly qualified by this cautionary statement.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/aphria-completes-german-tender-process-and-receives-fifth-culitvation-license-in-germany-300853722.html
SOURCE Aphria Inc.